Cargando…
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically c...
Autores principales: | Cannon, Christopher P., Gropper, Savion, Bhatt, Deepak L., Ellis, Stephen G., Kimura, Takeshi, Lip, Gregory Y.H., Steg, Ph. Gabriel, ten Berg, Jurriën M., Manassie, Jenny, Kreuzer, Jörg, Blatchford, Jon, Massaro, Joseph M., Brueckmann, Martina, Ferreiros Ripoll, Ernesto, Oldgren, Jonas, Hohnloser, Stefan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108471/ https://www.ncbi.nlm.nih.gov/pubmed/27565018 http://dx.doi.org/10.1002/clc.22572 |
Ejemplares similares
-
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
por: Oldgren, Jonas, et al.
Publicado: (2019) -
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017) -
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
por: Nicolau, José C., et al.
Publicado: (2020) -
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE‐DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
por: Eccleston, David S., et al.
Publicado: (2021) -
Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018)